文献速递生殖医学妇科

早期乳腺癌患者为卵母细胞玻璃化冷冻行卵巢刺激未改变无病生存率和总生存率

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer.
PubMed 文献 · Reprod Biomed Online · 2019-07-10

本队列研究纳入259例早期乳腺癌患者,其中148例接受卵巢刺激,111例未接受,患者治疗时间为2008年1月至2016年12月,随访至5年。结果显示两组复发率和死亡率无显著差异,无病生存时间和总生存时间亦无显著差异,作者认为卵巢刺激在早期乳腺癌患者中似长期安全。

要点

  • 暴露组与非暴露组在肿瘤、淋巴结和转移分类、Nottingham分级、激素受体状态、肿瘤分子表型、组织学和病理分期方面具有可比性。
  • 复发在暴露组为9/148例(6.1%),在非暴露组为15/111例(13.5%),无显著差异。
  • 死亡在暴露组为2/148例(1.4%),在非暴露组为4/111例(3.6%),总生存率相当;作者认为卵巢刺激在早期乳腺癌患者中似长期安全。

核心结论

  • 本研究提示,早期乳腺癌患者行卵巢刺激在长期看来是安全的。

研究设计与样本

  • 本队列研究纳入259例早期乳腺癌患者,其中148例接受卵巢刺激,111例未接受。
  • 患者治疗时间为2008年1月至2016年12月。
  • 以根治性手术时间作为计算无病生存时间和总生存率的起点,随访至5年。

主要发现

  • 暴露组与非暴露组在肿瘤、淋巴结和转移分类、Nottingham分级、激素受体状态、肿瘤分子表型、组织学和病理分期方面具有可比性。
  • 暴露组较非暴露组年轻。
  • 复发在暴露组为9/148例(6.1%),在非暴露组为15/111例(13.5%),无显著差异。
  • 暴露组平均无病生存时间为63.9个月(95%CI:61.5-66.4),非暴露组为60.6个月(95%CI:56.9-64.2),无显著差异(log-rank [Mantel-Cox]检验)。
  • 死亡在暴露组为2/148例(1.4%),在非暴露组为4/111例(3.6%);暴露组平均总生存时间为67.2个月(95%CI:66.2-68.2),非暴露组为65.9个月(95%CI:64.0-67.9),无显著差异(log-rank [Mantel-Cox]检验)。

临床怎么用

  • 作者认为,早期乳腺癌患者行卵巢刺激在长期看来是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? DESIGN: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. RESULTS: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tumour molecular phenotype, histology and pathology stage. The exposed group was younger than the non-exposed. Recurrences occurred in 9/148 women (6.1%) in the exposed group and 15/111 women (13.5%) in the non-exposed group, with no significant difference. The mean disease-free survival time was 63.9 months (95% confidence interval [CI]: 61.5-66.4) in the exposed group and 60.6 months (95% CI: 56.9-64.2) in the non-exposed, with no significant difference (log-rank [Mantel-Cox] test). Overall survival rates were comparable; 2/148 (1.4%) and 4/111 (3.6%) patients died, in exposed and non-exposed groups, respectively, during the period analysed. Mean overall survival times were 67.2 months (95% CI: 66.2-68.2) in the exposed group and 65.9 months (95% CI: 64.0-67.9) in the unexposed, with no significant difference (log-rank [Mantel-Cox] test). CONCLUSIONS: This study suggests that ovarian stimulation in patients with early-stage breast cancer is safe in the long term.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Muñoz E, Domingo J, De Castro G, et al. Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer. Reprod Biomed Online. 2019. PMID: 31564650. doi:10.1016/j.rbmo.2019.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。